Edward A. Stadtmauer, MD

Shraim R, Shi G, Li Y, Xu J, Fuller T, Martinez Z, McGrath L, Aplenc R, Cairo MS, Glisovic-Aplenc T, Gill SI, Grupp SA, Hermiston ML, Hogarty MD, Horton T, Hughes AD, June CH, Mullighan CG, Newman H, Pölönen P, Stadtmauer E, Tan K, Tasian SK, Teachey L, Teachey HE, Turn CS, Wang'ondu RW, Wood B, Wertheim G, Teachey DT, Yang JJ, Diorio C. Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies , Blood: 2026

Chen GM, Jain A, Gering DT, Satulovsky J, Datta S, Lai P, Karar J, Gonzalez VE, Alexander K, Chew A, Jadlowsky JK, Ruella M, Paruzzo L, Amses KR, Rech AJ, Stadtmauer EA, Frey NV, Hexner EO, Porter DL, Cohen AD, Gill SI, Garfall AL, Schuster SJ, Mo KC, Liang SI, Spasic M, Levine BL, Siegel DL, Ramírez-Fernández A, Cabanski CR, Yang E, Mackall CL, Bushman FD, Good Z, John Wherry E, June CH, Fraietta JA. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer , Nat Biomed Eng: 2026

Patel H, Hubbeling H, Yu K, Carpenter M, LaRiviere MJ, Plastaras JP, Cohen AD, Kapur S, Vogl DT, Waxman AJ, Stadtmauer EA, Garfall AL, Susanibar-Adaniya S. Outcomes of radiation integrated with T-cell-engaging bispecific antibodies in relapsed/refractory multiple myeloma , Blood Adv, 10: 2026,1395-1399

Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA. CD4(+) T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy , Nat Med: 2026

Yu KL, Ho M, Paruzzo L, Stella F, Patel H, Hasanali ZS, Kapur S, Waxman AJ, Vogl DT, Stadtmauer EA, Fraietta JA, Ruella M, Cohen AD, Garfall AL, Susanibar-Adaniya S. Outcomes of relapse after teclistamab therapy in multiple myeloma , Blood Cancer J, 15: 2025,193

Shan X, Kuiper R, Ding C, Munshi PN, Stadtmauer EA, Susanibar-Adaniya SP. Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study , Haematologica, 110: 2025,2839-2843

Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ. Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen , Eur J Haematol: 2025

Stalker M, Garfall A, Cohen A, Vogl DT, Djulbegovic M, Susanibar-Adaniya S, Stadtmauer E, Megherea O, Waxman AJ. Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis , Eur J Haematol: 2025

Ho M, Paruzzo L, Minehart J, Voruganti T, Devi P, Vogl DT, Cohen AD, Garfall AL, Waxman AJ, Kapur S, Stadtmauer EA, Susanibar Adaniya S, Longworth S. Nontuberculous mycobacterial infections following teclistamab in multiple myeloma , Haematologica, 110: 2025,1436-1442

Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702 , Leukemia: 2025